Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes products for rare cardiopulmonary diseases in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection given by continuous intravenous and subcutaneous infusion, and is developing L606, an investigational liposomal formulation of treprostinil in phase III trials for PAH and PH-ILD. The company offers PRINT technology for engineering uniform drug particles with precise control over size, three-dimensional geometric shape, and chemical composition, and has license agreements with Pharmosa Biopharm, Vectura, the University of North Carolina at Chapel Hill, GlaxoSmithKline, and Alcon, plus a promotion agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.
It shows the core business is growing fast, which is the main force pushing LQDA up.
▼
Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.
This is the biggest new negative force, directly threatening a major part of Yutrepia's market.
▼
Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.
It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.
▲
Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.
It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.
Q3 2026
▲2▼2
Yutrepia Launch Booms, Then Patent Ruling Threatens Key Market
▲
Yutrepia launch exceeds expectations Yutrepia's launch delivered strong growth: annualized revenue hit about $520 million, with $300 million in first-half sales, over 5,000 patients started, and four straight profitable quarters. Analysts raised estimates as the stock more than doubled.
This is the main positive force behind the stock's rise during the period.
▼
Patent ruling threatens PH-ILD market A Delaware court ruled that Yutrepia infringes a United Therapeutics patent covering PH-ILD use, threatening a key market and future sales. This legal setback reversed earlier momentum and weighed heavily on the stock.
This is the major negative event that changed the stock's trajectory.
▼
Analyst downgrades and price target cuts Wells Fargo, BTIG, and Raymond James downgraded the stock and sharply cut price targets following the patent ruling, reflecting reduced confidence in future sales and earnings.
These downgrades amplified the negative impact of the patent ruling on the stock price.
▲
FDA Fast Track for Raynaud's The FDA granted Fast Track status for Yutrepia in scleroderma-related Raynaud's phenomenon, a smaller, early-stage opportunity that partly offsets the negative patent news.
This is a new positive development that provides some counterbalance to the negative drivers.
News & notes movingLQDA
United States
LQDA▼
Liquidia Extends Losses as Wells Fargo Downgrades on Patent Setback
Liquidia is heading for its worst weekly decline after a legal setback in its patent dispute with United Therapeutics, as Wells Fargo added to a wave of downgrades on the North Carolina-based company. Wells Fargo analyst Benjamin Burnett downgraded Liquidia to Equal Weight from Overweight and slashed his price target to $30 from $108 per share, sending the stock lower for a third straight session. The ruling found that Liquidia violated U.S. Patent 11,826,327, which relates to United Therapeutics' best-selling lung therapy Tyvaso, and Burnett argued it adds uncertainty to L606, a treprostinil formulation the company is currently advancing. The analyst is not convinced of the company's prospects on appeal and wants more clarity on expansion opportunities for L606, which he says could be blocked for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. BTIG and Raymond James were among other brokerages that downgraded Liquidia this week in reaction to the litigation update.
United Therapeutics Jumps 12.5% After Delaware Court Rules Liquidia's Yutrepia Infringes Patent
United Therapeutics shares ended the last trading session 12.5% higher at $541.89 after a Delaware court ruled that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD. The ruling could lead to restrictions on Yutrepia's PH-ILD use, potentially reducing competition for United Therapeutics' Tyvaso and Tyvaso DPI products, and the company could further benefit from potential monetary damages related to Liquidia's past infringement, although the final remedies remain pending. The drugmaker is expected to post quarterly earnings of $6.38 per share in its upcoming report, a year-over-year change of -10.9%, on revenues of $792.64 million, down 0.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days, and the stock currently carries a Zacks Rank #3 (Hold).
UTHR · Regulation · Positive Court ruling that Liquidia's Yutrepia infringes UTHR's patent could reduce competition for Tyvaso and lead to monetary damages.
FDA Grants Fast Track to Liquidia's Yutrepia for Scleroderma-Linked Raynaud's
Liquidia Corporation announced that the FDA has granted Fast Track designation to Yutrepia (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis, or SSc-RP. Yutrepia, an inhaled dry-powder formulation of treprostinil developed with Liquidia's proprietary PRINT technology, was approved by the FDA in May 2025 for PAH and pulmonary hypertension associated with interstitial lung disease. Liquidia plans to initiate RE-WARM, a phase IIa, randomized, open-label, dose-finding study of Yutrepia in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon attacks, at up to 30 U.S. sites, with the study expected to begin in October 2026 and primary completion targeted for February 2027. Since its commercial launch in June 2025, Yutrepia has generated approximately $300.3 million in sales in the first half of 2026, with about 5,900 unique prescriptions and more than 5,000 patients initiated. The company also plans to evaluate the therapy in pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, while competing in the PAH market against United Therapeutics' Tyvaso and Tyvaso DPI and Insmed's clinical-stage TPIP and INS1148 programs.
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▲Demand
LQDA · Regulation · Positive FDA granted Fast Track designation to Liquidia's Yutrepia for Raynaud's phenomenon associated with systemic sclerosis.
LQDA · Demand · Positive Yutrepia generated about $300.3 million in first-half 2026 sales with roughly 5,900 prescriptions and over 5,000 patients initiated since launch.
Liquidia Corporation's Yutrepia has generated approximately $300.3 million in sales during the first half of 2026 since its June 2025 launch, with 5,900 unique prescriptions and more than 5,000 patients initiated on therapy. The inhaled dry-powder treprostinil formulation, approved by the FDA in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, uses Liquidia's proprietary PRINT technology to enable higher doses than marketed inhaled therapies. Liquidia faces competition from United Therapeutics' Tyvaso and Tyvaso DPI, as well as Johnson & Johnson's Ventavis and Uptravi, while advancing pipeline candidate L606 in a phase III study. Shares of LQDA have surged 99% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has moved to $2.57 from $2.97 in the past 60 days.
Liquidia shares fell 20% week to date after the biotech's second-quarter earnings slightly missed analyst expectations. Revenue surged to nearly $171.7 million from $8.8 million a year earlier, driven almost entirely by sales of its pulmonary hypertension drug Yutrepia, which launched in June 2025. The company posted a GAAP net profit of $74.7 million, or $0.74 per share, versus a year-ago loss of $41.6 million, but that was just below the $0.76 per share consensus forecast. Liquidia also updated progress on L-606, its only remaining developmental program, which uses the same molecule as Yutrepia with a different formulation and delivery method. The stock had risen 155% year-to-date before earnings, leaving little room for anything short of a blowout quarter.
Lenovo, Victoria's Secret, and Liquidia Break Out on Earnings Momentum
Lenovo Group, Victoria's Secret, and Liquidia Corporation are breaking out on strong earnings momentum and bullish chart patterns. Lenovo posted record fiscal 2025/26 revenue of $83.1 billion, up 20% year over year, with AI-related revenue more than doubling to 33% of total sales, and its Zacks Consensus Estimate for the current year has climbed 43% over the past 60 days. Victoria's Secret reported first quarter net sales of $1.56 billion, a 15% increase, with adjusted earnings of $0.60 per share roughly doubling expectations, and its current-quarter consensus estimate has risen 20.3%. Liquidia's first-quarter net product sales reached approximately $130 million, nearly matching its full-year 2025 total, and earnings estimates have trended sharply higher as the company posted its third consecutive profitable quarter. All three stocks carry a Zacks Rank #1 (Strong Buy) and have recently broken above bullish consolidation patterns, signaling potential for further gains.
Liquidia Corporation Set to Report Q2 Earnings With Strong Yutrepia Momentum
Liquidia Corporation is scheduled to report second-quarter results on August 12, with the Zacks Consensus Estimate for sales at $165.25 million and earnings per share at 70 cents. The company has a strong earnings surprise history, beating estimates in three of the last four quarters by an average of 54.4%, though its Earnings ESP for the upcoming report is 0.00% despite a Zacks Rank of 1. Yutrepia, its inhaled dry-powder treprostinil therapy approved in May 2025 and launched in June 2025, has driven rapid growth, surpassing a $500 million annualized revenue run rate within its first year and recording more than 4,500 unique prescriptions, around 3,750 patient starts, and nearly 980 prescribing physicians. Liquidia also generates revenue through a profit-sharing agreement with Sandoz for generic treprostinil injection and is advancing L606, an extended-release treprostinil formulation, in clinical trials. Shares have surged 151.7% year to date, and management remains confident in achieving at least $1 billion in annual revenues by 2027, funded entirely through operating cash flow.
Biotech Stocks IKT, HALO, JAZZ, CORT, LQDA Hit 52-Week Highs
Several biotech stocks reached 52-week highs on July 24, 2026, driven by upcoming quarterly reports and regulatory milestones. Inhibikase Therapeutics hit $2.53 after its lead candidate IKT-001 received FDA Orphan Drug designation for pulmonary arterial hypertension, with a global Phase 3 trial underway. Jazz Pharmaceuticals reached $256.75, supported by 19% first-quarter revenue growth to $1.1 billion and progress with Zanidatamab in breast cancer studies. Halozyme Therapeutics climbed to $82.99 following a 42% year-over-year revenue increase to $376 million in the first quarter and full-year guidance of $1.71 billion to $1.81 billion. Corcept Therapeutics touched $97.63, with first-quarter revenue rising to $164 million from $157 million a year earlier, ahead of its July 29 earnings report. Liquidia Corporation hit $91.10, buoyed by $130 million in first-quarter YUTREPIA sales and a net income of $52 million.
Liquidia jumps as judge criticizes United Therapeutics in patent dispute
Liquidia Corp. rose 8% after a judge criticized United Therapeutics in a long-standing patent dispute. Judge Richard G. Andrews wrote that United Therapeutics failed to explain how changing about ten keystrokes in an 8,500-word original while representing the original is unchanged is anything other than deceptive and backdated. The judge asked United Therapeutics to provide the identity of the lawyer who altered the original interrogatory response. United Therapeutics ticked lower by 1.2%.
Liquidia's Yutrepia Generates $130 Million in First-Quarter 2026 Sales
Liquidia Corporation's Yutrepia generated approximately $130 million in first-quarter 2026 sales following its June 2025 launch. The inhaled dry-powder treprostinil therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease has seen robust adoption, with more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 physicians prescribing the drug. Liquidia is also advancing L606, an investigational liposomal treprostinil formulation, in clinical trials and plans to expand Yutrepia into additional indications including PH-COPD, IPF, PPF, and Raynaud's phenomenon. The company faces competition from United Therapeutics' Tyvaso franchise and Johnson & Johnson's PAH portfolio, while generic Tyvaso entered the U.S. market in 2026. Liquidia shares have surged 134.6% year to date and currently carry a Zacks Rank of 1, or Strong Buy.
UTHR · Competition · Negative Liquidia's Yutrepia competes with United Therapeutics' Tyvaso franchise, and generic Tyvaso entered the market in 2026, pressuring UT's position.
JNJ · Competition · Neutral Johnson & Johnson's PAH portfolio is mentioned as a competitor, but no specific impact on J&J is detailed.
Seeking Alpha Quant rates Centene top healthcare stock, Doximity bottom ahead of Q2 earnings
Seeking Alpha's quantitative framework has identified Centene Corporation as the highest-rated healthcare stock with a Strong Buy rating of 4.97, while Doximity received the lowest rating of 1.21, a Strong Sell, as the second-quarter earnings season begins. The Health Care Select Sector SPDR Fund ETF, which tracks the sector and represents roughly 12.12% of the S&P 500, has risen 4.52% year-to-date, trailing the benchmark index's 10.06% advance. In the second quarter, the broader healthcare sector posted a modest 8.78% return, while the Technology index skyrocketed 43.49%. The top five Strong Buy stocks with market caps above $2 billion also include Liquidia Corporation at 4.95, BrightSpring Health Services at 4.95, LifeStance Health Group at 4.93, and PACS Group at 4.92. The bottom five Strong Sell or Sell stocks include TransMedics Group at 1.26, CSL Limited at 1.30, Zoetis at 1.34, and EssilorLuxottica ADR at 1.39.
Laughing Water Capital Updates on Liquidia Corp. Highlight YUTREPIA Launch and Patent Litigation
Laughing Water Capital released its second-quarter 2026 investor letter, highlighting Liquidia Corporation and its drug YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension interstitial lung diseases. The firm noted the launch has been fantastic and the company plans to pursue additional indications, but remains in litigation with United Therapeutics over alleged patent infringement. The judge has not issued a ruling almost a year after the case concluded, though Laughing Water Capital believes a worst-case outcome pulling the drug from the PH-ILD market is off the table. Liquidia shares closed at $71.21 on July 13, 2026, with a market capitalization of $6.33 billion, and gained 390.76% over the past 52 weeks.
Liquidia's Yutrepia generates $130 million in first-quarter 2026 sales
Liquidia Corporation's lead drug Yutrepia generated approximately $130 million in first-quarter 2026 sales, helping the company post its third consecutive profitable quarter. The inhaled dry-powder formulation of treprostinil, approved by the FDA in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, has seen more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 prescribing physicians since its June 2025 launch. Liquidia faces intense competition from United Therapeutics' extensive PAH portfolio, which includes injectable, oral, and inhaled treprostinil products, as well as from Johnson & Johnson's Uptravi and Opsumit. The company is planning studies to evaluate Yutrepia for additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Liquidia shares have surged 126% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has risen to $3.02 from $1.50 over the past 60 days.
United Therapeutics Stock Rises 14% Year to Date on Pipeline Progress
United Therapeutics shares have gained 14% year to date, outperforming the industry's 0.8% decline, driven by clinical breakthroughs and improved long-term growth visibility. In March 2026, the company announced positive phase III data from the TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, which exceeded the strong results previously reported in TETON-2, supporting a planned FDA supplemental application. The company also reported positive phase III data for its PAH candidate ralinepag from the ADVANCE OUTCOMES study and intends to submit a new drug application in the second half of 2026. United Therapeutics is advancing its organ manufacturing platform, including FDA clearance for a phase I study of its xenotransplantation heart candidate UHeart and premarket approval for the LungFX ex-vivo lung perfusion device. However, the company faces increasing competitive pressure on its core PAH franchise, with nebulized Tyvaso sales declining after loss of exclusivity and the launch of Liquidia's Yutrepia, which posted 44% sequential sales growth in the first quarter of 2026.
Liquidia Shares Surge 129.7% Year to Date on Strong Yutrepia Sales
Liquidia Corporation shares have soared 129.7% year to date, far outpacing the industry's 7% growth. The company's lead drug Yutrepia, an inhaled dry-powder treprostinil approved in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, generated approximately $130 million in sales in the first quarter of 2026. As of April 30, 2026, Yutrepia had received more than 4,500 unique patient prescriptions since its June 2025 launch, with about 3,750 patients initiating treatment and a prescription-to-start conversion rate of 85% or higher. The strong uptake helped Liquidia achieve its third consecutive profitable quarter, with net income reaching $52.9 million. The Zacks Consensus Estimate for 2026 earnings per share has risen to $3.02 from $1.50 over the past 60 days, and the stock currently trades at 7.95 times forward sales.
5 Biotech Stocks That Delivered 100% To 300% Gains
Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.
Liquidia Corporation's YUTREPIA launch drives rapid revenue growth and profitability
Liquidia Corporation has scaled annualized revenue from virtually zero to approximately $520 million within three full quarters of launching YUTREPIA for pulmonary hypertension, with quarterly revenue climbing from $8.8 million to $132.9 million. Roughly 75% of new patient starts are treatment-naive, indicating market expansion rather than just competitor displacement. EBITDA improved from substantial losses to approximately $61.9 million, with a 54% margin in the third quarter post-launch, and net income turned strongly positive while gross margins remained above 90%. Management guides toward approximately $1 billion of revenue in 2027, supported by a new manufacturing facility in 2026 that will triple capacity, and the company has an estimated $6 billion addressable market. Key risks include ongoing litigation from United Therapeutics and potential moderation of launch growth as penetration increases.
LQDA · Demand · Positive YUTREPIA launch drives rapid revenue growth and profitability, with 75% of new patient starts being treatment-naive, indicating market expansion
UTHR · Competition · Negative Liquidia's YUTREPIA is competing with United Therapeutics' products, and ongoing litigation from United Therapeutics is noted as a key risk for Liquidia
Zacks Screens Three Low-Beta Stocks as Market Uncertainty Persists
Zacks Investment Research highlights Liquidia Corporation, Flexsteel Industries, and Argan as low-beta stocks worth buying amid persistent market uncertainty. The screen selected stocks with a beta between 0 and 0.6, a positive four-week price change, average 20-day volume above 50,000, a price of at least $5, and a Zacks Rank of 1, or Strong Buy. Liquidia is seeing rapid adoption of its YUTREPIA treatment, has achieved profitability, and is generating positive cash flow. Flexsteel Industries, a furniture manufacturer, benefits from a debt-free balance sheet and strong cash position. Argan holds a $2.8 billion backlog and no debt, positioning it to meet rising demand for power infrastructure.
AGX · Demand · Positive Argan holds a $2.8 billion backlog and no debt, positioning it to meet rising demand for power infrastructure.
FLXS · Capital · Positive Flexsteel Industries benefits from a debt-free balance sheet and strong cash position, highlighted as a low-beta buy.
LQDA · Demand · Positive Liquidia is seeing rapid adoption of its YUTREPIA treatment, has achieved profitability, and is generating positive cash flow.
USA